Products for Research Use Only
RegisterLogin

AZD1897

CAT: 0804-HY-164460-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-164460-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
AZD1897 is a PIM1, PIM2, and PIM3 inhibitor with IC50 values of less than 3 nM for these three PIM kinases. AZD1897 exhibits anticancer activity and synergistically inhibits the activity of acute myeloid leukemia (AML) cells in combination with Capivasertib. This synergistic inhibitory effect is achieved through the inhibition of the mTOR and MCL1 pathways[1][2].
CAS Number
1204181-93-0
UNSPSC
12352005
Target
Pim
Type
Reference compound
Related Pathways
JAK/STAT Signaling
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/azd1897.html
Purity
99.69
Solubility
DMSO : 20 mg/mL (ultrasonic; warming; adjust pH to 2 with 1 M HCl; heat to 60°C)
Smiles
O=C(NC/1=O)SC1=C/C2=CC=CC(OC(C)C)=C2N3C[C@H](N)CCC3
Molecular Formula
C18H23N3O3S
Molecular Weight
361.46
References & Citations
[1]Dakin LA, et al. Discovery of novel benzylidene-1,3-thiazolidine-2,4-diones as potent and selective inhibitors of the PIM-1, PIM-2, and PIM-3 protein kinases. Bioorg Med Chem Lett. 2012 Jul 15;22 (14) :4599-604. |[2]Meja K, et al. PIM and AKT kinase inhibitors show synergistic cytotoxicity in acute myeloid leukaemia that is associated with convergence on mTOR and MCL1 pathways. Br J Haematol. 2014 Oct;167 (1) :69-79.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
PIM1; PIM2; PIM3

Related Products

CatalogName
HY-121070AZD1092
HY-15950-01AZD1981
HY-126329-01AZD9898
HY-13224-01AZD4877
HY-50914-01AZD5597
HY-U00257-01AZD1979
HY-109566-01AZD1390
HY-15950R-01AZD1981 (Standard)
HY-13224AAZD4877 (hydrochloride)

Popular Products